Global and United States Galectin-3 Inhibitor Market Report & Forecast 2022-2028

• Description
• Table of Contents
• Table of Figures
• PDF Download

• Description
• Table of Contents
• Table of Figures
• PDF Download

Market Analysis and Insights: Global and United States Galectin-3 Inhibitor Market
This report focuses on global and United States Galectin-3 Inhibitor market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Galectin-3 Inhibitor market size is estimated to be worth US$  million in 2022 and is forecast to a readjusted size of US$  million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, Natural accounting for % of the Galectin-3 Inhibitor global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Diabetes was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

In United States the Galectin-3 Inhibitor market size is expected to grow from US$  million in 2021 to US$  million by 2028, at a CAGR of % during the forecast period 2022-2028.

Global Galectin-3 Inhibitor Scope and Market Size
Galectin-3 Inhibitor market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Galectin-3 Inhibitor market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Galectin-3 Inhibitor market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type
    Natural
    Synthetic

Segment by Application
    Diabetes
    Heart Failure
    Asthma
    Rheumatoid Arthritis
    Other

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        China Taiwan
        Indonesia
        Thailand
        Malaysia
    Latin America
        Mexico
        Brazil
        Argentina
        Colombia
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

By Company
    GlycoMimetics (US)
    Galectin Therapeutics Inc (US)
    G3 Pharmaceuticals (India)
    iTeos (US)
    MandalMed, Inc (US)
    Angion (US)
    Novartis AG (Switzerland)
    Galecto Biotech (Denmark)
    Pfizer Inc. (US)
    Lilly (US)

 1 Study Coverage
    1.1 Galectin-3 Inhibitor Revenue in Galectin-3 Inhibitor Business (2017-2022) & (US$ Million) Introduction
    1.2 Global Galectin-3 Inhibitor Outlook 2017 VS 2022 VS 2028
        1.2.1 Global Galectin-3 Inhibitor Market Size for the Year 2017-2028
        1.2.2 Global Galectin-3 Inhibitor Market Size for the Year 2017-2028
    1.3 Galectin-3 Inhibitor Market Size, United States VS Global, 2017 VS 2022 VS 2028
        1.3.1 The Market Share of United States Galectin-3 Inhibitor in Global, 2017 VS 2022 VS 2028
        1.3.2 The Growth Rate of Galectin-3 Inhibitor Market Size, United States VS Global, 2017 VS 2022 VS 2028
    1.4 Galectin-3 Inhibitor Market Dynamics
        1.4.1 Galectin-3 Inhibitor Industry Trends
        1.4.2 Galectin-3 Inhibitor Market Drivers
        1.4.3 Galectin-3 Inhibitor Market Challenges
        1.4.4 Galectin-3 Inhibitor Market Restraints
    1.5 Study Objectives
    1.6 Years Considered

 2 Galectin-3 Inhibitor by Type
    2.1 Galectin-3 Inhibitor Market Segment by Type
        2.1.1 Natural
        2.1.2 Synthetic
    2.2 Global Galectin-3 Inhibitor Market Size by Type (2017, 2022 & 2028)
    2.3 Global Galectin-3 Inhibitor Market Size by Type (2017-2028)
    2.4 United States Galectin-3 Inhibitor Market Size by Type (2017, 2022 & 2028)
    2.5 United States Galectin-3 Inhibitor Market Size by Type (2017-2028)

 3 Galectin-3 Inhibitor by Application
    3.1 Galectin-3 Inhibitor Market Segment by Application
        3.1.1 Diabetes
        3.1.2 Heart Failure
        3.1.3 Asthma
        3.1.4 Rheumatoid Arthritis
        3.1.5 Other
    3.2 Global Galectin-3 Inhibitor Market Size by Application (2017, 2022 & 2028)
    3.3 Global Galectin-3 Inhibitor Market Size by Application (2017-2028)
    3.4 United States Galectin-3 Inhibitor Market Size by Application (2017, 2022 & 2028)
    3.5 United States Galectin-3 Inhibitor Market Size by Application (2017-2028)

 4 Global Galectin-3 Inhibitor Competitor Landscape by Company
    4.1 Global Galectin-3 Inhibitor Market Size by Company
        4.1.1 Top Global Galectin-3 Inhibitor Companies Ranked by Revenue (2021)
        4.1.2 Global Galectin-3 Inhibitor Revenue by Player (2017-2022)
    4.2 Global Galectin-3 Inhibitor Concentration Ratio (CR)
        4.2.1 Galectin-3 Inhibitor Market Concentration Ratio (CR) (2017-2022)
        4.2.2 Global Top 5 and Top 10 Largest Companies of Galectin-3 Inhibitor in 2021
        4.2.3 Global Galectin-3 Inhibitor Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
    4.3 Global Galectin-3 Inhibitor Headquarters, Revenue in Galectin-3 Inhibitor Business (2017-2022) & (US$ Million) Type
        4.3.1 Global Galectin-3 Inhibitor Headquarters and Area Served
        4.3.2 Global Galectin-3 Inhibitor Companies Revenue in Galectin-3 Inhibitor Business (2017-2022) & (US$ Million) Type
        4.3.3 Date of International Companies Enter into Galectin-3 Inhibitor Market
    4.4 Companies Mergers & Acquisitions, Expansion Plans
    4.5 United States Galectin-3 Inhibitor Market Size by Company
        4.5.1 Top Galectin-3 Inhibitor Players in United States, Ranked by Revenue (2021)
        4.5.2 United States Galectin-3 Inhibitor Revenue by Players (2020, 2021 & 2022)

 5 Global Galectin-3 Inhibitor Market Size by Region
    5.1 Global Galectin-3 Inhibitor Market Size by Region: 2017 VS 2022 VS 2028
    5.2 Global Galectin-3 Inhibitor Market Size by Region (2017-2028)
        5.2.1 Global Galectin-3 Inhibitor Market Size by Region: 2017-2022
        5.2.2 Global Galectin-3 Inhibitor Market Size by Region (2023-2028)

 6 Segment in Region Level & Country Level
    6.1 North America
        6.1.1 North America Galectin-3 Inhibitor Market Size YoY Growth 2017-2028
        6.1.2 North America Galectin-3 Inhibitor Market Facts & Figures by Country (2017, 2022 & 2028)
        6.1.3 United States
        6.1.4 Canada
    6.2 Asia-Pacific
        6.2.1 Asia-Pacific Galectin-3 Inhibitor Market Size YoY Growth 2017-2028
        6.2.2 Asia-Pacific Galectin-3 Inhibitor Market Facts & Figures by Region (2017, 2022 & 2028)
        6.2.3 China
        6.2.4 Japan
        6.2.5 South Korea
        6.2.6 India
        6.2.7 Australia
        6.2.8 China Taiwan
        6.2.9 Indonesia
        6.2.10 Thailand
        6.2.11 Malaysia
    6.3 Europe
        6.3.1 Europe Galectin-3 Inhibitor Market Size YoY Growth 2017-2028
        6.3.2 Europe Galectin-3 Inhibitor Market Facts & Figures by Country (2017, 2022 & 2028)
        6.3.3 Germany
        6.3.4 France
        6.3.5 U.K.
        6.3.6 Italy
        6.3.7 Russia
    6.4 Latin America
        6.4.1 Latin America Galectin-3 Inhibitor Market Size YoY Growth 2017-2028
        6.4.2 Latin America Galectin-3 Inhibitor Market Facts & Figures by Country (2017, 2022 & 2028)
        6.4.3 Mexico
        6.4.4 Brazil
        6.4.5 Argentina
        6.4.6 Colombia
    6.5 Middle East and Africa
        6.5.1 Middle East and Africa Galectin-3 Inhibitor Market Size YoY Growth 2017-2028
        6.5.2 Middle East and Africa Galectin-3 Inhibitor Market Facts & Figures by Country (2017, 2022 & 2028)
        6.5.3 Turkey
        6.5.4 Saudi Arabia
        6.5.5 UAE

 7 Company Profiles
    7.1 GlycoMimetics (US)
        7.1.1 GlycoMimetics (US) Company Details
        7.1.2 GlycoMimetics (US) Business Overview
        7.1.3 GlycoMimetics (US) Galectin-3 Inhibitor Introduction
        7.1.4 GlycoMimetics (US) Revenue in Galectin-3 Inhibitor Business (2017-2022)
        7.1.5 GlycoMimetics (US) Recent Development
    7.2 Galectin Therapeutics Inc (US)
        7.2.1 Galectin Therapeutics Inc (US) Company Details
        7.2.2 Galectin Therapeutics Inc (US) Business Overview
        7.2.3 Galectin Therapeutics Inc (US) Galectin-3 Inhibitor Introduction
        7.2.4 Galectin Therapeutics Inc (US) Revenue in Galectin-3 Inhibitor Business (2017-2022)
        7.2.5 Galectin Therapeutics Inc (US) Recent Development
    7.3 G3 Pharmaceuticals (India)
        7.3.1 G3 Pharmaceuticals (India) Company Details
        7.3.2 G3 Pharmaceuticals (India) Business Overview
        7.3.3 G3 Pharmaceuticals (India) Galectin-3 Inhibitor Introduction
        7.3.4 G3 Pharmaceuticals (India) Revenue in Galectin-3 Inhibitor Business (2017-2022)
        7.3.5 G3 Pharmaceuticals (India) Recent Development
    7.4 iTeos (US)
        7.4.1 iTeos (US) Company Details
        7.4.2 iTeos (US) Business Overview
        7.4.3 iTeos (US) Galectin-3 Inhibitor Introduction
        7.4.4 iTeos (US) Revenue in Galectin-3 Inhibitor Business (2017-2022)
        7.4.5 iTeos (US) Recent Development
    7.5 MandalMed, Inc (US)
        7.5.1 MandalMed, Inc (US) Company Details
        7.5.2 MandalMed, Inc (US) Business Overview
        7.5.3 MandalMed, Inc (US) Galectin-3 Inhibitor Introduction
        7.5.4 MandalMed, Inc (US) Revenue in Galectin-3 Inhibitor Business (2017-2022)
        7.5.5 MandalMed, Inc (US) Recent Development
    7.6 Angion (US)
        7.6.1 Angion (US) Company Details
        7.6.2 Angion (US) Business Overview
        7.6.3 Angion (US) Galectin-3 Inhibitor Introduction
        7.6.4 Angion (US) Revenue in Galectin-3 Inhibitor Business (2017-2022)
        7.6.5 Angion (US) Recent Development
    7.7 Novartis AG (Switzerland)
        7.7.1 Novartis AG (Switzerland) Company Details
        7.7.2 Novartis AG (Switzerland) Business Overview
        7.7.3 Novartis AG (Switzerland) Galectin-3 Inhibitor Introduction
        7.7.4 Novartis AG (Switzerland) Revenue in Galectin-3 Inhibitor Business (2017-2022)
        7.7.5 Novartis AG (Switzerland) Recent Development
    7.8 Galecto Biotech (Denmark)
        7.8.1 Galecto Biotech (Denmark) Company Details
        7.8.2 Galecto Biotech (Denmark) Business Overview
        7.8.3 Galecto Biotech (Denmark) Galectin-3 Inhibitor Introduction
        7.8.4 Galecto Biotech (Denmark) Revenue in Galectin-3 Inhibitor Business (2017-2022)
        7.8.5 Galecto Biotech (Denmark) Recent Development
    7.9 Pfizer Inc. (US)
        7.9.1 Pfizer Inc. (US) Company Details
        7.9.2 Pfizer Inc. (US) Business Overview
        7.9.3 Pfizer Inc. (US) Galectin-3 Inhibitor Introduction
        7.9.4 Pfizer Inc. (US) Revenue in Galectin-3 Inhibitor Business (2017-2022)
        7.9.5 Pfizer Inc. (US) Recent Development
    7.10 Lilly (US)
        7.10.1 Lilly (US) Company Details
        7.10.2 Lilly (US) Business Overview
        7.10.3 Lilly (US) Galectin-3 Inhibitor Introduction
        7.10.4 Lilly (US) Revenue in Galectin-3 Inhibitor Business (2017-2022)
        7.10.5 Lilly (US) Recent Development

 8 Research Findings and Conclusion

 9 Appendix
    9.1 Research Methodology
        9.1.1 Methodology/Research Approach
        9.1.2 Data Source
    9.2 Author Details
    9.3 Disclaimer

List of Tables
    Table 1. Galectin-3 Inhibitor Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Galectin-3 Inhibitor Market Trends
    Table 3. Galectin-3 Inhibitor Market Drivers
    Table 4. Galectin-3 Inhibitor Market Challenges
    Table 5. Galectin-3 Inhibitor Market Restraints
    Table 6. Global Galectin-3 Inhibitor Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Galectin-3 Inhibitor Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Galectin-3 Inhibitor Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Galectin-3 Inhibitor Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Galectin-3 Inhibitor Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Galectin-3 Inhibitor Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Galectin-3 Inhibitor Revenue Share by Player, 2017-2022
    Table 13. Global Galectin-3 Inhibitor Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Galectin-3 Inhibitor by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Galectin-3 Inhibitor as of 2021)
    Table 15. Top Players of Galectin-3 Inhibitor in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Galectin-3 Inhibitor Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Galectin-3 Inhibitor Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Galectin-3 Inhibitor Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Galectin-3 Inhibitor Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Galectin-3 Inhibitor Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Galectin-3 Inhibitor Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Galectin-3 Inhibitor Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Galectin-3 Inhibitor Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Galectin-3 Inhibitor Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Galectin-3 Inhibitor Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Galectin-3 Inhibitor Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Galectin-3 Inhibitor Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Galectin-3 Inhibitor Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. GlycoMimetics (US) Company Details
    Table 31. GlycoMimetics (US) Business Overview
    Table 32. GlycoMimetics (US) Galectin-3 Inhibitor Product
    Table 33. GlycoMimetics (US) Revenue in Galectin-3 Inhibitor Business (2017-2022) & (US$ Million)
    Table 34. GlycoMimetics (US) Recent Development
    Table 35. Galectin Therapeutics Inc (US) Company Details
    Table 36. Galectin Therapeutics Inc (US) Business Overview
    Table 37. Galectin Therapeutics Inc (US) Galectin-3 Inhibitor Product
    Table 38. Galectin Therapeutics Inc (US) Revenue in Galectin-3 Inhibitor Business (2017-2022) & (US$ Million)
    Table 39. Galectin Therapeutics Inc (US) Recent Development
    Table 40. G3 Pharmaceuticals (India) Company Details
    Table 41. G3 Pharmaceuticals (India) Business Overview
    Table 42. G3 Pharmaceuticals (India) Galectin-3 Inhibitor Product
    Table 43. G3 Pharmaceuticals (India) Revenue in Galectin-3 Inhibitor Business (2017-2022) & (US$ Million)
    Table 44. G3 Pharmaceuticals (India) Recent Development
    Table 45. iTeos (US) Company Details
    Table 46. iTeos (US) Business Overview
    Table 47. iTeos (US) Galectin-3 Inhibitor Product
    Table 48. iTeos (US) Revenue in Galectin-3 Inhibitor Business (2017-2022) & (US$ Million)
    Table 49. iTeos (US) Recent Development
    Table 50. MandalMed, Inc (US) Company Details
    Table 51. MandalMed, Inc (US) Business Overview
    Table 52. MandalMed, Inc (US) Galectin-3 Inhibitor Product
    Table 53. MandalMed, Inc (US) Revenue in Galectin-3 Inhibitor Business (2017-2022) & (US$ Million)
    Table 54. MandalMed, Inc (US) Recent Development
    Table 55. Angion (US) Company Details
    Table 56. Angion (US) Business Overview
    Table 57. Angion (US) Galectin-3 Inhibitor Product
    Table 58. Angion (US) Revenue in Galectin-3 Inhibitor Business (2017-2022) & (US$ Million)
    Table 59. Angion (US) Recent Development
    Table 60. Novartis AG (Switzerland) Company Details
    Table 61. Novartis AG (Switzerland) Business Overview
    Table 62. Novartis AG (Switzerland) Galectin-3 Inhibitor Product
    Table 63. Novartis AG (Switzerland) Revenue in Galectin-3 Inhibitor Business (2017-2022) & (US$ Million)
    Table 64. Novartis AG (Switzerland) Recent Development
    Table 65. Galecto Biotech (Denmark) Company Details
    Table 66. Galecto Biotech (Denmark) Business Overview
    Table 67. Galecto Biotech (Denmark) Galectin-3 Inhibitor Product
    Table 68. Galecto Biotech (Denmark) Revenue in Galectin-3 Inhibitor Business (2017-2022) & (US$ Million)
    Table 69. Galecto Biotech (Denmark) Recent Development
    Table 70. Pfizer Inc. (US) Company Details
    Table 71. Pfizer Inc. (US) Business Overview
    Table 72. Pfizer Inc. (US) Galectin-3 Inhibitor Product
    Table 73. Pfizer Inc. (US) Revenue in Galectin-3 Inhibitor Business (2017-2022) & (US$ Million)
    Table 74. Pfizer Inc. (US) Recent Development
    Table 75. Lilly (US) Company Details
    Table 76. Lilly (US) Business Overview
    Table 77. Lilly (US) Galectin-3 Inhibitor Product
    Table 78. Lilly (US) Revenue in Galectin-3 Inhibitor Business (2017-2022) & (US$ Million)
    Table 79. Lilly (US) Recent Development
    Table 80. Research Programs/Design for This Report
    Table 81. Key Data Information from Secondary Sources
    Table 82. Key Data Information from Primary Sources
List of Figures
    Figure 1. Galectin-3 Inhibitor Product Picture
    Figure 2. Global Galectin-3 Inhibitor Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Galectin-3 Inhibitor Market Size 2017-2028 (US$ Million)
    Figure 4. United States Galectin-3 Inhibitor Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Galectin-3 Inhibitor Market Size 2017-2028 (US$ Million)
    Figure 6. United States Galectin-3 Inhibitor Market Share in Global 2017-2028
    Figure 7. Galectin-3 Inhibitor Report Years Considered
    Figure 8. Product Picture of Natural
    Figure 9. Product Picture of Synthetic
    Figure 10. Global Galectin-3 Inhibitor Market Share by Type in 2022 & 2028
    Figure 11. Global Galectin-3 Inhibitor Market Size by Type (2017-2028) & (US$ Million)
    Figure 12. Global Galectin-3 Inhibitor Market Share by Type (2017-2028)
    Figure 13. United States Galectin-3 Inhibitor Market Share by Type in 2022 & 2028
    Figure 14. United States Galectin-3 Inhibitor Market Size by Type (2017-2028) & (US$ Million)
    Figure 15. United States Galectin-3 Inhibitor Market Share by Type (2017-2028)
    Figure 16. Product Picture of Diabetes
    Figure 17. Product Picture of Heart Failure
    Figure 18. Product Picture of Asthma
    Figure 19. Product Picture of Rheumatoid Arthritis
    Figure 20. Product Picture of Other
    Figure 21. Global Galectin-3 Inhibitor Market Share by Application in 2022 & 2028
    Figure 22. Global Galectin-3 Inhibitor Market Size by Application (2017-2028) & (US$ Million)
    Figure 23. Global Galectin-3 Inhibitor Market Share by Application (2017-2028)
    Figure 24. United States Galectin-3 Inhibitor Market Share by Application in 2022 & 2028
    Figure 25. United States Galectin-3 Inhibitor Market Size by Application (2017-2028) & (US$ Million)
    Figure 26. United States Galectin-3 Inhibitor Market Share by Application (2017-2028)
    Figure 27. North America Galectin-3 Inhibitor Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 28. United States Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 29. Canada Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 30. Europe Galectin-3 Inhibitor Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 31. Germany Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 32. France Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 33. U.K. Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. Italy Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. Russia Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 36. Asia-Pacific Galectin-3 Inhibitor Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 37. China Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 38. Japan Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. South Korea Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. India Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. Australia Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. China Taiwan Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Indonesia Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Thailand Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Malaysia Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Latin America Galectin-3 Inhibitor Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 47. Mexico Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Brazil Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 49. Argentina Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Colombia Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Middle East & Africa Galectin-3 Inhibitor Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 52. Turkey Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 53. Saudi Arabia Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 54. UAE Galectin-3 Inhibitor Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 55. GlycoMimetics (US) Revenue Growth Rate in Galectin-3 Inhibitor Business (2017-2022)
    Figure 56. Galectin Therapeutics Inc (US) Revenue Growth Rate in Galectin-3 Inhibitor Business (2017-2022)
    Figure 57. G3 Pharmaceuticals (India) Revenue Growth Rate in Galectin-3 Inhibitor Business (2017-2022)
    Figure 58. iTeos (US) Revenue Growth Rate in Galectin-3 Inhibitor Business (2017-2022)
    Figure 59. MandalMed, Inc (US) Revenue Growth Rate in Galectin-3 Inhibitor Business (2017-2022)
    Figure 60. Angion (US) Revenue Growth Rate in Galectin-3 Inhibitor Business (2017-2022)
    Figure 61. Novartis AG (Switzerland) Revenue Growth Rate in Galectin-3 Inhibitor Business (2017-2022)
    Figure 62. Galecto Biotech (Denmark) Revenue Growth Rate in Galectin-3 Inhibitor Business (2017-2022)
    Figure 63. Pfizer Inc. (US) Revenue Growth Rate in Galectin-3 Inhibitor Business (2017-2022)
    Figure 64. Lilly (US) Revenue Growth Rate in Galectin-3 Inhibitor Business (2017-2022)
    Figure 65. Bottom-up and Top-down Approaches for This Report
    Figure 66. Data Triangulation
    Figure 67. Key Executives Interviewed

Market Analysis and Insights: Global and United States Galectin-3 Inhibitor Market
This report focuses on global and United States Galectin-3 Inhibitor market, also covers the segmentation data of other regions in regional level and county level.

Due to the COVID-19 pandemic, the global Galectin-3 Inhibitor market size is estimated to be worth US$  million in 2022 and is forecast to a readjusted size of US$  million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, by Type, Natural accounting for % of the Galectin-3 Inhibitor global market in 2021, is projected to value US$  million by 2028, growing at a revised % CAGR from 2022 to 2028. While by Application, Diabetes was the leading segment, accounting for over  percent market share in 2021, and altered to an  % CAGR throughout this forecast period.

In United States the Galectin-3 Inhibitor market size is expected to grow from US$  million in 2021 to US$  million by 2028, at a CAGR of % during the forecast period 2022-2028.

Global Galectin-3 Inhibitor Scope and Market Size
Galectin-3 Inhibitor market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Galectin-3 Inhibitor market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.

For United States market, this report focuses on the Galectin-3 Inhibitor market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.

Segment by Type
    Natural
    Synthetic

Segment by Application
    Diabetes
    Heart Failure
    Asthma
    Rheumatoid Arthritis
    Other

By Region
    North America
        United States
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        China Taiwan
        Indonesia
        Thailand
        Malaysia
    Latin America
        Mexico
        Brazil
        Argentina
        Colombia
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

By Company
    GlycoMimetics (US)
    Galectin Therapeutics Inc (US)
    G3 Pharmaceuticals (India)
    iTeos (US)
    MandalMed, Inc (US)
    Angion (US)
    Novartis AG (Switzerland)
    Galecto Biotech (Denmark)
    Pfizer Inc. (US)
    Lilly (US)